BACKGROUND: The outcome and prognosis of ovarian cancer is highly variable. The objective of this study was to compare survival and clinicopathological prognostic factors with the expression levels of two matrix metalloproteinases (MMP) and fibronectin as tumor invasion and metastasis markers in ovarian cancer patients. MATERIALS AND METHODS: Histologically-verified epithelial ovarian tumours from 27 patients were studied. The latent and the activated forms of MMP-2 and MMP-9 were measured as gelatinase activity from tumour extracts and from serum and ascites samples by a zymographic technique. The fibronectin content was quantified by immunoblotting and densitometric analysis. Molecular marker levels were correlated to clinicopathological parameters such as survival and disease recurrence during the median postoperative follow-up period of 30 months. RESULTS: The levels of MMP-9 and fibronectin, but not those of MMP-2, were significantly higher in tumour tissues and in the ascites fluid of the recurrent patient group and the patient group who did not survive, as compared to the non-reccurent cases. CONCLUSION: Our data support that high expression of MMP-9 and fibronectin indicate poor prognosis for ovarian cancer patients who have similar clinicopathological prognostic factors.
BACKGROUND: The outcome and prognosis of ovarian cancer is highly variable. The objective of this study was to compare survival and clinicopathological prognostic factors with the expression levels of two matrix metalloproteinases (MMP) and fibronectin as tumor invasion and metastasis markers in ovarian cancerpatients. MATERIALS AND METHODS: Histologically-verified epithelial ovarian tumours from 27 patients were studied. The latent and the activated forms of MMP-2 and MMP-9 were measured as gelatinase activity from tumour extracts and from serum and ascites samples by a zymographic technique. The fibronectin content was quantified by immunoblotting and densitometric analysis. Molecular marker levels were correlated to clinicopathological parameters such as survival and disease recurrence during the median postoperative follow-up period of 30 months. RESULTS: The levels of MMP-9 and fibronectin, but not those of MMP-2, were significantly higher in tumour tissues and in the ascites fluid of the recurrent patient group and the patient group who did not survive, as compared to the non-reccurent cases. CONCLUSION: Our data support that high expression of MMP-9 and fibronectin indicate poor prognosis for ovarian cancerpatients who have similar clinicopathological prognostic factors.
Authors: Imran Rizvi; Jonathan P Celli; Conor L Evans; Adnan O Abu-Yousif; Alona Muzikansky; Brian W Pogue; Dianne Finkelstein; Tayyaba Hasan Journal: Cancer Res Date: 2010-11-09 Impact factor: 12.701
Authors: Erica L Johnson; Rajesh Singh; Shailesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard Journal: World J Surg Oncol Date: 2010-07-22 Impact factor: 2.754
Authors: Suzanne Miyamoto; L Renee Ruhaak; Carol Stroble; Michelle R Salemi; Brett Phinney; Carlito B Lebrilla; Gary S Leiserowitz Journal: J Proteome Res Date: 2016-08-23 Impact factor: 4.466
Authors: Karen D Cowden Dahl; Jaime Symowicz; Yan Ning; Elisa Gutierrez; David A Fishman; Brian P Adley; M Sharon Stack; Laurie G Hudson Journal: Cancer Res Date: 2008-06-15 Impact factor: 12.701
Authors: Peter Brünker; Christian Klein; Martina Geiger; Kay-Gunnar Stubenrauch; Johannes Sam; Wolfgang F Richter; Gregor Jordan; Jan Eckmann; Carina Hage; Valeria Nicolini; Anne Freimoser-Grundschober; Mirko Ritter; Matthias E Lauer; Henning Stahlberg; Philippe Ringler; Jigar Patel; Eric Sullivan; Sandra Grau-Richards; Stefan Endres; Sebastian Kobold; Pablo Umaña Journal: Nat Commun Date: 2020-06-24 Impact factor: 14.919